Fiche société
University of California, Irvine
Traitements, essais et publications liés.
Traitements11programmes
Essais5liés
Publications14liées
SourceDBlocale
Traitements
11| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| NortriptylineTinnitus represents one of the most common and distressing otologic problems, and it causes various somatic and psychological disorders that interfere with the quality of life. Despite too many research projects on finding the mechanism of tinnitus, its pathophysiology remains poorly understood. It is well understood that many factors, such as poor education, lower income, or occupational, and recreational activity associated with high noise exposure, influence the prevalence and risk of tinnitus. Although the economic and emotional impact of tinnitus is large, there is currently no FDA-approved medication to treat this condition. However, there are pharmacological options to address the stress, anxiety, and depression that are caused by tinnitus. In this project, the investigators intend to use medications for patients with acute tinnitus to decrease the impact of tinnitus in their daily lives and activities. There are some studies on medications treating tinnitus; however, there are few randomized clinical trials to prove the efficacy of the treatment. The frequency and loudness of tinnitus will be measured before and after the course. Functional MRI of the brain will be obtained to view any changes that may occur before and after the treatment. | Migraine | Phase 4 | À vérifier | United States | À vérifier |
| nortriptyline + topiramateMeniere's disease (MD) is a chronic disease with a variety of fluctuating signs and symptoms, which include vertigo, hearing loss, tinnitus (ringing noise in the ear), aural pressure (feeling of ear fullness), and disequilibrium (lack of stability). Vertigo represents one of the most common and distressing problems in MD patients, and it causes various somatic and psychological disorders that interfere with the patient's quality of life. Despite the large economic and emotional impact of symptoms in MD patients, there is no FDA-approved medication to treat this debilitating condition. As such, our objective in this study is to evaluate the therapeutic potential of novel medications in treating MD that have previously shown astonishing promise in our clinical practice. | Migraine | Phase 4 | Traitement symptomatique | United States | À vérifier |
| paroxetineThis is a comparative drug trial involving patients with clinically definite Multiple Sclerosis and documented neuropathic pain. Patients will be randomized to receive treatment with either paroxetine or pregabalin. After dose titration, participants will complete various pain scale assessments at several points during the study in order to determine the effectiveness of their assigned pain medication. | Migraine, SEP | Phase 4 | Traitement symptomatique | United States | À vérifier |
| Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal CarcinomatosisThis is a pilot study gathering and using samples and data from patients with gastrointestinal peritoneal carcinomatosis. Participants will be asked for permission to provide blood and ascites/peritoneal wash fluid, tumor samples during their planned surgical procedure. | Cancer | Non applicable | À vérifier | United States | À vérifier |
| topiramateThe purpose of this study is to compare the reduction in the number of severe headache days at six months in people with chronic migraine treated with topiramate and propranolol versus those treated with topiramate and a placebo. | Migraine | Phase 4 | À vérifier | United States | À vérifier |
| VerapamilTinnitus represents one of the most common and distressing otologic problems, and it causes various somatic and psychological disorders that interfere with the quality of life. Despite too many research projects on finding the mechanism of tinnitus, its pathophysiology remains poorly understood. It is well understood that many factors, such as poor education, lower income, or occupational, and recreational activity associated with high noise exposure, influence the prevalence and risk of tinnitus. Although the economic and emotional impact of tinnitus is large, there is currently no FDA-approved medication to treat this condition. However, there are pharmacological options to address the stress, anxiety, and depression that are caused by tinnitus. In this project, the investigators intend to use medications for patients with acute tinnitus to decrease the impact of tinnitus in their daily lives and activities. There are some studies on medications treating tinnitus; however, there are few randomized clinical trials to prove the efficacy of the treatment. The frequency and loudness of tinnitus will be measured before and after the course. Functional MRI of the brain will be obtained to view any changes that may occur before and after the treatment. | Migraine | Phase 4 | À vérifier | United States | À vérifier |
| paroxetineThis is a comparative drug trial involving patients with clinically definite Multiple Sclerosis and documented neuropathic pain. Patients will be randomized to receive treatment with either paroxetine or pregabalin. After dose titration, participants will complete various pain scale assessments at several points during the study in order to determine the effectiveness of their assigned pain medication. | SEP | Phase 3 | Traitement symptomatique | Canada | À vérifier |
| NortriptylineTinnitus represents one of the most common and distressing otologic problems, and it causes various somatic and psychological disorders that interfere with the quality of life. Despite too many research projects on finding the mechanism of tinnitus, its pathophysiology remains poorly understood. It is well understood that many factors, such as poor education, lower income, or occupational, and recreational activity associated with high noise exposure, influence the prevalence and risk of tinnitus. Although the economic and emotional impact of tinnitus is large, there is currently no FDA-approved medication to treat this condition. However, there are pharmacological options to address the stress, anxiety, and depression that are caused by tinnitus. In this project, the investigators intend to use medications for patients with acute tinnitus to decrease the impact of tinnitus in their daily lives and activities. There are some studies on medications treating tinnitus; however, there are few randomized clinical trials to prove the efficacy of the treatment. The frequency and loudness of tinnitus will be measured before and after the course. Functional MRI of the brain will be obtained to view any changes that may occur before and after the treatment. | Migraine | Phase 4 | À vérifier | United States | À vérifier |
| Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal CarcinomatosisThis is a pilot study gathering and using samples and data from patients with gastrointestinal peritoneal carcinomatosis. Participants will be asked for permission to provide blood and ascites/peritoneal wash fluid, tumor samples during their planned surgical procedure. | Cancer | Non applicable | À vérifier | United States | À vérifier |
| nortriptyline + topiramateMeniere's disease (MD) is a chronic disease with a variety of fluctuating signs and symptoms, which include vertigo, hearing loss, tinnitus (ringing noise in the ear), aural pressure (feeling of ear fullness), and disequilibrium (lack of stability). Vertigo represents one of the most common and distressing problems in MD patients, and it causes various somatic and psychological disorders that interfere with the patient's quality of life. Despite the large economic and emotional impact of symptoms in MD patients, there is no FDA-approved medication to treat this debilitating condition. As such, our objective in this study is to evaluate the therapeutic potential of novel medications in treating MD that have previously shown astonishing promise in our clinical practice. | Migraine | Phase 4 | Traitement symptomatique | United States | À vérifier |
| NortriptylineTinnitus represents one of the most common and distressing otologic problems, and it causes various somatic and psychological disorders that interfere with the quality of life. Despite too many research projects on finding the mechanism of tinnitus, its pathophysiology remains poorly understood. It is well understood that many factors, such as poor education, lower income, or occupational, and recreational activity associated with high noise exposure, influence the prevalence and risk of tinnitus. Although the economic and emotional impact of tinnitus is large, there is currently no FDA-approved medication to treat this condition. However, there are pharmacological options to address the stress, anxiety, and depression that are caused by tinnitus. In this project, the investigators intend to use medications for patients with acute tinnitus to decrease the impact of tinnitus in their daily lives and activities. There are some studies on medications treating tinnitus; however, there are few randomized clinical trials to prove the efficacy of the treatment. The frequency and loudness of tinnitus will be measured before and after the course. Functional MRI of the brain will be obtained to view any changes that may occur before and after the treatment. | Migraine | Phase 4 | À vérifier | Oman | À vérifier |
Essais cliniques
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Nortriptyline | Migraine | Phase 4 | NCT07856056 | Nortriptyline Compared With Amitriptyline for Migraine Prevention at SQUH | NOT_YET_RECRUITING |
| nortriptyline + topiramate | Migraine | Phase 4 | NCT05582837 | Treatment of Meniere's Disease With Migraine Medications | RECRUITING |
| Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis | Cancer | Non applicable | NCT05844865 | Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis | RECRUITING |
| Nortriptyline | Migraine | Phase 4 | NCT06799169 | Management of Acute Tinnitus With Migraine Medications | SUSPENDED |
| paroxetine | SEP | Phase 3 | NCT00291148 | Neuropathic Pain Assessment Comparing Pregabalin and Paroxetine in Management of MS-induced Neuropathic Pain | COMPLETED |
Publications
14| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Verapamil | An artificial model of ATP-binding cassette mediated transport. | Colloids and surfaces. B, Biointerfaces | ||
| Nortriptyline | Exploring health professionals' perspectives and preferences in the treatment of post-stroke fatigue and mental health disorders: an Australian qualitative vignette-based study. | The International journal of pharmacy practice | ||
| topiramate | Interactions between SSR504734, a selective glycine transporter type 1 inhibitor, and antiseizure drugs: pharmacodynamic and pharmacokinetic studies in mice. | Neuropharmacology | ||
| paroxetine | Psychopharmacological treatment of patients with heart failure: A narrative review of antidepressants and anxiolytics. | Current problems in cardiology | ||
| paroxetine | Redox modulation contributes to the antidepressant-like and neuroprotective effects of 7-chloro-4-(phenylselanyl)quinoline in an Alzheimer's disease model. | Redox report : communications in free radical research | ||
| paroxetine | Modelling post-traumatic stress disorder-major depressive disorder comorbidity in rats: impaired α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor signalling is consistent with synergistic behavioural and cognitive deficits. | European journal of psychotraumatology | ||
| topiramate | Antiseizure medication use in pregnancy and the risk of poor fetal growth in the EURAP international registry: a prospective cohort study. | The Lancet. Neurology | ||
| topiramate | Systemic Medications as Triggers of Acute Angle-Closure Glaucoma: A Narrative Review. | Journal of clinical medicine | ||
| paroxetine | The impact of fluoxetine on the aversive effects of lysergic acid diethylamide. | Experimental and clinical psychopharmacology | ||
| paroxetine | Xiaoyao San exerts antidepressant effects via the gut microbiota-brain axis: An integrative fMRI and multiomics study. | Journal of pharmaceutical and biomedical analysis | ||
| topiramate | Weight mitigation and tolerability of adjunctive topiramate in acute pediatric psychiatry: a retrospective real-world analysis. | Frontiers in psychiatry | ||
| topiramate | Projected budget impact of pharmacotherapy scenarios for obesity and related conditions in Peru: A national survey analysis of 76,819 participants. | Obesity pillars | ||
| paroxetine | Drug-induced dysphagia: Analysis of age and time of onset profiles using a Japanese pharmacovigilance database. | International journal of clinical pharmacology and therapeutics | ||
| paroxetine | Effects of antidepressant administration on physical performance and perceived exertion in athletes: systematic review and meta-analysis. | International journal of clinical pharmacy |